We applied whole-exome sequencing (WES) for identification of an underlying genetic cause of a disease in a family presented with fatal infantile hyperthermia. Analysis of WES results revealed novel, deleterious compound missense mutations, Val160Ala and Pro233Thr, in the synthesis of cytochrome C oxidase 2 gene (SCO2) encoding a mitochondrial protein, Sco2, which is important for cytochrome C oxidase (COX) synthesis. Autosomal recessive mutations in SCO2 are known to be associated with COX deficiency recognized as fatal infantile cardio-encephalomyopathy (604272, OMIM). The Val160Ala and Pro233Thr mutations occurred in the conserved thioredoxin domain of Sco2 and predicted to disrupt protein folding and interaction of Sco2 with other proteins. Our results show applicability of WES in identification of disease-causing mutations and in establishing molecular diagnosis of severe, infantile onset disorder with a challenging diagnosis.
INTRODUCTION
Whole-exome sequencing (WES) has proven to be an extremely valuable and cost-effective tool for uncovering disease genes and establishing molecular diagnosis in many rare disorders. 1,2 This technology is particularly important for atypical, sporadic cases and small families for which the underlying genetic cause is not identified by traditional genetic studies.
In this study, we report a successful application of WES for identification of an underlying genetic cause of a disease in a family with a history of fatal infantile hyperthermia. We highlight the utility of WES in determining a molecular diagnosis when a detailed phenotype and clinical diagnosis of the patient was limited. The molecular diagnosis was based on the finding of novel, likely deleterious compound missense mutations, Val160Ala and Pro233Thr, in the synthesis of cytochrome C oxidase 2 gene (SCO2). 3 SCO2 encodes a metallochaperone, Sco2, which has an essential role in the biogenesis of cytochrome C oxidase (COX). 4 Autosomal recessive mutations in SCO2 associated with COX deficiency known as fatal infantile cardio-encephalomyopathy (604272, OMIM). 3-7
MATERIALS AND METHODS
An Indian couple who have lost three children was referred for a genetic study of malignant hyperthermia (MH) because of the children's suspected history of persistent hyperthermia in a hot environment. The marriage was nonconsanguineous, pregnancy was normal and neonatal complications were denied (Supplementary Table S1 ). All children were male, deceased at 5, 9 and 10 months of age. The hyperthermia started about 1-2 months before death, and was continuous (439 1C) and not associated with any major infection. None of the children were investigated for autopsy or muscle biopsy. The grandparents and parents were consented to participate in the genetic study ( Figure 1a) . The DNA from the last deceased boy was available. This study was approved by the Institutional Review Board of Uniformed Services University.
A family trio, consisting of parents and a deceased proband, was subjected to WES. Details of WES and data analysis are given in the Supplementary Information. Complete sequencing of the ryanodine receptor type 1 gene (RYR1) was performed in the deceased proband as described. 8 RESULTS Dominant mutations in RYR1 are associated with MH, a pharmacogenetic disease of muscle, in which hyperthermia, among a constellation of other symptoms and signs, occurs on exposure to anesthetic agents. 9, 10 Although MH is a drug-induced disorder, cases of sudden death during heat challenge, and febrile illness in the absence of triggering anesthetics have been reported. 8, 11 Therefore, we analyzed entire RYR1 in the deceased proband and the results were negative. Although the degree of hyperthermia was impressive in the proband, stiffness and rigidity typical of MH crises were not observed (Supplementary Table S1 ). In addition, the proband responded to antipyretics and his blood gas results revealed respiratory alkalosis. These signs are not consistent with clinical findings in MH. 9 As a result of the proband's metabolic acidosis, we hypothesized that the proband is likely to suffer from a rare metabolic disorder and performed WES on the proband and his parents. WES resulted in 481% of the targets reaching 430 Â coverage (Supplementary Table  S2 ). We used analysis pipeline to select missense single-nucleotide polymorphisms and coding insertions-deletions that are not present in publicly available exome databases 12, 13 and determined variants impact with PolyPhen and SIFT. WES results for other causative genes for MH including CACNA1S, CASQ1 and CACNA2D1 were negative. We further identified six compound heterozygous and two homozygous variants under autosomal recessive inheritance (Supplementary Table S3 ). Of these, compound heterozygous variants in three genes, ANKD35, SCO2 and XAB2, were noteworthy as they introduced missense mutations with damaging effects. However, only both Val160Ala and Pro233Thr mutations in SCO2 were absent in the publicly available data on exome sequencing of 47500 European and African Americans. 12,13 SCO2 encodes a mitochondrial protein, Sco2, which participates in COX assembly by providing copper to the catalytic CuA site on COX subunit II. 4 Recessive mutations in SCO2 cause COX deficiency known as fatal infantile cardio-encephalopathy characterized by progressive hypertrophic cardiomyopathy in the neonatal period with respiratory insufficiency, hypotonia and metabolic acidosis. 3-7 Death occurs during the first year of life mainly due to cardiac or respiratory failure. Inheritance of newly identified mutations was confirmed by Sanger sequencing (Figure 1a and b). Segregation analysis in extended family shows Val160Ala occurred de novo in the father and the mother to be a heterozygous carrier of the Pro233Thr mutation (Figure 1a) .
The Val160Ala and Pro233Thr mutations are located in conserved thioredoxin domain of the protein and mutate residues that are conserved across species (Figure 1c) . The Val160Ala mutation lies at the beginning of b4 whereas the Pro233Thr is located in the loop between the last two b strands of the protein (Figure 2) . The side chain of Val160 is part of the hydrophobic core at the interface between helix a1 and the central b-sheet. 14 This hydrophobic core also includes Leu151, mutation of which into a proline is one of known pathogenic missense mutations in the human SCO2. 15 The Leu151Pro mutation is thought to weaken the interactions between helix a1 and the central b-sheet, thereby destabilizing the protein fold and increasing its turnover rate. 14 Similarly, mutation of Val160Ala is likely to have the same effect on the protein stability by disrupting the same hydrophobic core. Pro233 is at the position i þ 1 of a b-turn, and the Pro233Thr mutation is likely to change the local structure at the turn and affect its interactions with the nearby loop between strands b2 and b3 (Figure 2) . It is possible that the surface around Pro233 is involved in the interactions of Sco2 with other proteins, and thus the variation because of the mutation may result in the loss of protein-protein interaction and the loss of the Sco2 function. 
DISCUSSION
This study reports unexpected finding of novel compound heterozygous SCO2 mutations, Val160Ala and Pro233Thr, in a proband referred for a genetic study of MH. The patient presented with a clinical picture, fatal hyperthermia and metabolic acidosis, which is similar to MH. However, his overall clinical signs, such as lack of rigidity during hyperthermia, response to antipyretics and respiratory alkalosis clearly differentiate the patient's metabolic crisis from MH. Although some patients with mitochondrial defects manifests MHlike reactions, or show increased susceptibility to MH by contracture testing 16, 17 the majority of patients with mitochondrial myopathies do not develop MH on receiving triggering anesthetics, suggesting a lack of association between these two conditions. 18 The Val160Ala and Pro233Thr mutations in SCO2 are likely to be deleterious. The Val160Ala mutation occurred at the same position with previously reported Val160Gly mutation in a 4-month-old girl with severe case of Sco2 deficiency. 19 Mapping of both mutations on the protein structure shows that Val160Ala is likely to disturb the protein folding, whereas Pro233Thr may affect Sco2 interaction with other proteins. The structural perturbations from these mutations will probably lead to loss of Sco2 function; that is, indispensable for COXII synthesis. In addition, both mutations were absent in 47500 publicly available exomes with a diverse ethnic background. 12, 13 Based on these findings, we suggest disease diagnosis as fatal infantile cardio-encephalopathy, which was not considered in the referral of the patient.
To date, at least 43 cases of Sco2 deficiency has been reported and all except 1 of them were patients with European ancestry. 3, [5] [6] [7] 19, 20 All patients of European ancestry carry Glu140Lys mutation either in the homozygous or compound heterozygous state. The only case of Sco2 deficiency not associated with Glu140Lys mutation was a patient with homozygous Gly193Ser mutation and the patient was born to consanguineous parents of Indian ancestry. 19 Finding of another Indian family with Sco2 deficiency not associated with common European Glu140Lys mutation demonstrates a regional difference in the distribution of SCO2 mutations.
Limitation of this study is a lack of functional analysis establishing pathogenic relevance of newly identified SCO2 mutations. Further studies to determine the pathogenic consequence of SCO2 mutations are warranted.
